Lab21

Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round. 

The clinical diagnostics company will use the funds to invest in a new UK-based manufacturing facility and to accelerate global growth.

Lab21 will serve as a non-exclusive distributor of the SelectMDx prostate cancer test in the UK.

Novacyt announced a €3.1 million ($3.8 million) private equity placement to open new markets and develop infectious disease diagnostics.

NEW YORK (GenomeWeb) — Molecular testing methods such as nucleic acid sequence-based amplification (NASBA) and qPCR, administered either in combination or separately, are superior to routinely used ELISA-based assays for diagnosing invasive aspergillosis, according to a newly published retrospect

NEW YORK (GenomeWeb) – Liquid-based cytology diagnostics firm Novacyt today announced its intention to combine with Lab21 in a stock-for-stock transaction valued at approximately €40 million ($34.1 million).

NEW YORK (GenomeWeb News) – UK diagnostics firm Lab21 today announced an expansion of a distribution agreement with Quidel to include AnDiaTec's real-time PCR tests in the UK.

French molecular diagnostics and clinical genomics services firm IntegraGen said this week that it has obtained exclusive rights to a microRNA biomarker that can help predict therapeutic outcomes in non-KRAS mutated metastatic colorectal cancer patients being treated with epiderm

Irish clinical diagnostics company Trinity Biotech has acquired the blood bank screening and certain molecular assets of UK-based personalized medicine and clinical diagnostics firm Lab21, the companies said today.

UK-based clinical diagnostics developer Lab21 said last week that it has inked an agreement with IntegraGen to develop a microRNA assay for colorectal cancer designed to improve patient outcomes.

Pages

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.